Literature DB >> 34351450

Postsurgical geometrical variations of tumor bed and brainstem during photon and proton therapy for pediatric tumors of the posterior fossa: dosimetric impact and predictive factors.

Stefania Volpe1,2, Pierre-Yves Bondiau3, Line Claude4, Audrey Claren3, Laetitia Padovani5, Hamza AlGhamdi3,6, Gwenaëlle Duhil De Benaze7, Lucas Opitz8, Guillaume Baudin9, Catherine Dejean3, Daniel Maneval3, Barbara Alicja Jereczek-Fossa10,11, Jérôme Doyen12.   

Abstract

PURPOSE: Brainstem radionecrosis is an important issue during the irradiation of tumors of the posterior fossa. The aim of the present study is to analyze postsurgical geometrical variations of tumor bed (TB) and brainstem (BS) and their impact on dosimetry.
METHODS: Retrospective collection of data from pediatric patients treated at a single institution. Availability of presurgical magnetic resonance imaging (MRI) was verified; availability of at least two postsurgical MRIs was considered a further inclusion criterion. The following metrics were analyzed: total volume, Dice similarity coefficient (DSC), and Haudsdorff distances (HD).
RESULTS: Fourteen patients were available for the quantification of major postsurgical geometrical variations of TB. DSC, HD max, and HD average values were 0.47 (range: 0.08;0.76), 11.3 mm (7.7;24.5), and 2.6 mm (0.7;6.7) between the first and the second postoperative MRI, respectively. Postsurgical geometrical variations of the BS were also observed. Coverage to the TB was reduced in one patient (D95: -2.9 Gy), while D2 to the BS was increased for the majority of patients. Overall, predictive factors for significant geometrical changes were presurgical gross tumor volume (GTV) > 33 mL, hydrocephaly at diagnosis, Luschka foramen involvement, and younger age (≤ 8 years).
CONCLUSION: Major volume changes were observed in this cohort, with some dosimetric impact. The use of a recent co-registration MRI is advised. The 2-3 mm HD average observed should be considered in the planning target volume/planning organ at risk volume (PTV/PRV) margin and/or robust optimization planning. Results from wider efforts are needed to verify our findings.
© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Central nervous system tumors; Pediatric radiation oncology; Protontherapy; Surgical bed; Treatment planning optimization

Mesh:

Year:  2021        PMID: 34351450     DOI: 10.1007/s00066-021-01828-8

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  33 in total

1.  Subsequent malignancies after photon versus proton radiation therapy.

Authors:  Justin E Bekelman; Timothy Schultheiss; Amy Berrington De Gonzalez
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-06-28       Impact factor: 7.038

Review 2.  Differential diagnosis of posterior fossa tumours in children: new insights.

Authors:  Felice D'Arco; Faraan Khan; Kshitij Mankad; Mario Ganau; Pablo Caro-Dominguez; Sotirios Bisdas
Journal:  Pediatr Radiol       Date:  2018-08-17

3.  Executive functioning, academic skills, and quality of life in pediatric patients with brain tumors post-proton radiation therapy.

Authors:  Lea M Ventura; Julie A Grieco; Casey L Evans; Karen A Kuhlthau; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock; Margaret B Pulsifer
Journal:  J Neurooncol       Date:  2017-12-06       Impact factor: 4.130

4.  Incidence of second malignancies among patients treated with proton versus photon radiation.

Authors:  Christine S Chung; Torunn I Yock; Kerrie Nelson; Yang Xu; Nancy L Keating; Nancy J Tarbell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-06-15       Impact factor: 7.038

5.  Comparing Intelligence Quotient Change After Treatment With Proton Versus Photon Radiation Therapy for Pediatric Brain Tumors.

Authors:  Lisa S Kahalley; M Douglas Ris; David R Grosshans; M Fatih Okcu; Arnold C Paulino; Murali Chintagumpala; Bartlett D Moore; Danielle Guffey; Charles G Minard; Heather H Stancel; Anita Mahajan
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

Review 6.  Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review.

Authors:  Kimberly J Johnson; Jennifer Cullen; Jill S Barnholtz-Sloan; Quinn T Ostrom; Chelsea E Langer; Michelle C Turner; Roberta McKean-Cowdin; James L Fisher; Philip J Lupo; Sonia Partap; Judith A Schwartzbaum; Michael E Scheurer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-09-05       Impact factor: 4.254

7.  Quality of life outcomes in proton and photon treated pediatric brain tumor survivors.

Authors:  Torunn I Yock; Sundeep Bhat; Jackie Szymonifka; Beow Y Yeap; Jennifer Delahaye; Sarah S Donaldson; Shannon M MacDonald; Margaret B Pulsifer; Kristen S Hill; Thomas F DeLaney; David Ebb; Mary Huang; Nancy J Tarbell; Paul Graham Fisher; Karen A Kuhlthau
Journal:  Radiother Oncol       Date:  2014-10-07       Impact factor: 6.280

8.  Proton Relative Biological Effectiveness - Uncertainties and Opportunities.

Authors:  Harald Paganetti
Journal:  Int J Part Ther       Date:  2018-09-21

9.  Cognitive and Adaptive Outcomes After Proton Radiation for Pediatric Patients With Brain Tumors.

Authors:  Margaret B Pulsifer; Haley Duncanson; Julie Grieco; Casey Evans; Irene Delgado Tseretopoulos; Shannon MacDonald; Nancy J Tarbell; Torunn I Yock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-06-06       Impact factor: 7.038

10.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

View more
  1 in total

1.  Adaptive Proton Therapy of Pediatric Head and Neck Cases Using MRI-Based Synthetic CTs: Initial Experience of the Prospective KiAPT Study.

Authors:  Christian Bäumer; Rezarta Frakulli; Jessica Kohl; Sindhu Nagaraja; Theresa Steinmeier; Rasin Worawongsakul; Beate Timmermann
Journal:  Cancers (Basel)       Date:  2022-05-25       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.